Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C01EB16

Ibuprofen Gen.Orph(Ibuprofen)

Ductus Arteriosus, Patent

Marketing Authorisation Holder: Gen.Orph

EMA Authorisation: 16/02/2024

INN: ibuprofen

Indication

Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ibuprofen Gen.Orph — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.